Download presentation
Presentation is loading. Please wait.
Published byTrevor Tippen Modified over 9 years ago
1
Barbara Rudolph, PhD, MSSW NAHDO Consultant
2
To enhance the value of statewide APCDs by cataloging measures and reporting practices To develop and disseminate APCD reporting guidance with considerations for state APCD systems To facilitate APCD planning and reporting activities across states thus reducing duplicative planning efforts
3
Review APCD Council site Review individual state APCD websites General Web Search Conference calls with State Work Group Review of Reporting and Measures Table by workgroup
4
States with Public Reports Maryland New Hampshire Utah Vermont Colorado (Planned) States with Websites Maine New Hampshire Massachusetts Washington Colorado (Planned)
5
UtilizationCost QualityEfficiency Population Health Scope of Measurement
6
Covered by all APCDs—using different types of measures Global—overall utilization, payer groups, health planning areas, service lines Provider specific—Utilization of inpatient, outpatient, ED, observation, specialty, primary care, chiropractic, osteopathic, dental, pharmacy, imaging Payer type—Utilization by Medicaid, SCHIP, CHIP, Medicare, Medicare Part D, Private payer, Employer Procedures/Conditions—Number of high cost procedures and conditions, knee, lumbar, mental health, screenings (cholesterol, diabetes, kidney disease), prescriptions for specific conditions
7
Most APCD’s address cost—(using different measures) Cost to Payer—PMPM costs, high cost area, profile reports on medical, dental, pharmacy costs by payer, high cost distribution by plan product type, plan payments, plan costs by procedure, plan costs by health service area, aggregated costs for commercial population, payments per day and per day’s supply by major therapeutic categories of drugs Cost to Patient—Total out-of-pocket cost, co-pays, co-insurance, deductible amounts, cost to uninsured vs insured, costs by procedure and by provider Provider Cost—by specialty, standardized pricing, compared for units of service and mix of service Cost by Procedure/Condition—measures for preventive health, ED Visit, radiology, common surgical procedures, maternity measures, CRG, Diagnosis, chronic conditions, pharmacy costs Episode Cost—Burden of illness by CRG, diabetes, asthma depression
8
Some APCD’s are reporting limited quality measures: Use of tools like MONAHRQ for reporting quality measures Use of NCQA (HEDIS) measures—for mental health and substance abuse, medical groups, hospitals Use of some process measures for medical groups (LDL_C, HbA1C, eye exams, ) Use of CMS measures for hospital care Use of HCAPHS patient experience of care Re-admission rates (both cost and quality)
9
Measures thought to address efficiency include: Admission rates for ambulatory sensitive conditions Rates for potentially avoidable ED visits Costs per procedure by provider Length of Stay 30-day Readmission Rates Variation in rates of imaging Pharmacy payments by hospital service area presented as PMPM; payments per day’s supply by major therapeutic categories of drugs by HAS Provider’s costs to others of the same specialty—costs by mix of ETG’s using standardized pricing
10
Prevalence of key chronic conditions Admission rates for ambulatory care sensitive conditions Geographic variations in utilization, cost and care High Cost areas for Medicaid and Commercial populations Trends in healthcare costs Overall measures such as PMPM by geography Percentage of total health care costs of the top five chronic conditions Asthma billed medical costs and amounts paid by age group Health screenings for chronic conditions in small areas Variation in imaging rates across geography Key contributors driving pharmacy payments Provider access measures
11
Draft Table
13
APCD’s that are most developed in terms of public reporting are those that have had APCD systems longer… New APCD’s have public plans for reporting, but because of data lag they are not yet reporting States with mandatory reporting tend to do more public reporting Voluntary collections are less likely to report publicly and those that do are more likely to use measures that do not distinguish between providers (e.g., process measures with 99% compliance) Wide variation in number of reports and, whether or not there is a “choice” website for the public, and utility of reporting
14
Large range of measures in use—when you see one of a kind measures—it is likely due to particular stakeholders Population health measures are plentiful; mainly utilizing geographic variation to examine prevalence of disease, access to care Certain types of measures are more expensive to produce—require risk adjustment or diagnostic/episodic groupers ; episode measurement very limited—due to complexity of decision rules, software, provider push back and other factors Quality measures are also limited given the availability of hundreds of endorsed measures—likely due to a focus on costs by stakeholders Some quality measures in use have little or no variation across providers—and therefore, very little utility Because of limitation on quality measures and episode measures— efficiency measures are also lean. No composite measures of efficiency in use. At this time, it would be very difficult to create benchmarks or to do regional/national analyses given the lack of consistency in measures used by APCDs
15
Transparency boundaries for voluntary collections Complex analytic boundaries for established APCDs Standardization Boundaries for all!
16
Provide a guidance document Provide a completed Table of Measures Provide a Knowledge Base Tool (when funding is available)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.